Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xenopax for GVHD Prevention in Thalassemia
NCT06657391Phase 2Recruiting
- Sponsor
- Rongrong Liu
- Start
- Oct 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of xenopax in graft-versus-host disease (GVHD) (2 arms), sponsored by Rongrong Liu. Primary endpoint: Incidence of Grade III-IV Acute Graft-versus-host Disease at 100 days. Started Oct 2024; status: recruiting.
02
Drugs
xenopax
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06657391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657391.